Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease
Sanofi ships BEYFORTUS doses to US healthcare providers and CDC for RSV prevention, ensuring access for eligible babies. A new FDA-approved filling line expands manufacturing capacity, with another line expected to boost supply for the 2024/2025 RSV season. BEYFORTUS is the first long-acting monoclonal antibody for RSV LRTD prevention in newborns and infants up to 24 months.
Reference News
Sanofi ships BEYFORTUS doses to US healthcare providers and CDC for RSV prevention, ensuring access for eligible babies. A new FDA-approved filling line expands manufacturing capacity, with another line expected to boost supply for the 2024/2025 RSV season. BEYFORTUS is the first long-acting monoclonal antibody for RSV LRTD prevention in newborns and infants up to 24 months.